Professional Documents
Culture Documents
Thrombophilia, Risk Factors and Prevention: Expert Review of Hematology
Thrombophilia, Risk Factors and Prevention: Expert Review of Hematology
To cite this article: Elena Campello, Luca Spiezia, Angelo Adamo & Paolo Simioni
(2019): Thrombophilia, risk factors and prevention, Expert Review of Hematology, DOI:
10.1080/17474086.2019.1583555
DOI: 10.1080/17474086.2019.1583555
Thrombophilia, risk factors and prevention
Elena Campello, Luca Spiezia, Angelo Adamo, Paolo Simioni*
Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED), Padova
University Hospital, Italy
t
ip
cr
us
an
*Corresponding author:
Paolo Simioni,
M
t
hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has
ip
greatly improved.
cr
Areas covered: Main causes of hereditary thrombophilia are summarized alongside new
prothrombotic mutations recently discovered. The main causes of acquired thrombophilia,
us
and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also
discussed together with other common acquired prothrombotic states characterized by an
an
increase of procoagulant factors and/or a decrease of natural anticoagulants. Finally,
suggestions for thromboprophylaxis in carriers of hereditary thrombophilia according to
current guidelines/evidence are made for the most challenging high-risk situations (i.e.
M
surgery, pregnancy, contraception, cancer, economy class syndrome) as well as for the
prevention of post-thrombotic syndrome.
ed
assessing the need and duration of prevention (primary prophylaxis). Prevention strategies
should be tailored to each patient and every situational risk factor. The knowledge of the
ce
t
state” is used as synonym of pre-thrombotic state even though the majority of patients with
ip
hypercoagulability will never develop thrombosis. The genetic mutations responsible for
cr
inherited hypercoagulability were mainly studied in families with a high incidence of
thrombotic manifestations [2]. Acquired diseases may also result in coagulation changes
us
that may predispose to a thrombotic tendency. Thrombophilia may therefore be defined as
either an inherited or acquired abnormality of the haemostasis predisposing the affected
subjects to venous and/or arterial thrombosis [3, 4] (Table 1). The focus of this review is to
an
evaluate the current knowledge on inherited and acquired thrombophilia and to summarize
of the main pathophysiologic pathways and prevention strategies for thrombosis.
M
Anticoagulant therapy and secondary presentation in patients with thrombophilia will not
be treated.
ed
2. Inherited thrombophilia
pt
mutation G20210A, accounting for about 50% to 70% of the diagnosed genetic
thrombophilia. The less frequent but more severe defects of antithrombin (AT), protein C
Ac
(PC) and protein S (PS) account for most of the remaining cases of diagnosed genetic
thrombophilia [5, 6, 7, 8]. More recently, new genetic defects responsible for severe
thrombophilia have been identified, and namely, pseudo-homozygosity for activated
protein C (APC) resistance, the hyperfunctional factor IX Padua, and the resistance to AT
[9, 10, 11]. And last but not least, ABO blood group is the most common genetic risk factor
for VTE [12]. Figure 1 summarizes known and currently diagnosed hereditary
thrombophilias. There is a large number of families (about 30-40%) with symptomatic
thrombophilia in which none of the known inherited conditions is identified. This
unexplained thrombophilia is very likely to be due to genetic mutations that are still
unknown.
2.1 Most frequent inherited thrombophilias – Factor V Leiden and prothrombin G20210A
mutations
Factor V Leiden (FVL) and prothrombin G20120A are inherited mutations resulting in the
so-called “gain-of function” for the correspondent procoagulant factors. FVL is an
autosomal dominant disorder related to a missense mutation in the F5 gene at G1691A
t
which substitutes the amino acid glutamine for arginine at position 506 (R506Q) [13]. This
ip
missense mutation (Arg506Gln) causes factor V resistance to inactivation by APC [14].
cr
Several point mutations in the F5 gene causing APC resistance have been identified in
different populations, including Arg306→Thr (FV Cambridge), Arg306→Gly (FV Hong
us
Kong), Ile359→Thr (FV Liverpool), Glu666→Asp (mechanism unknown), and Ala512→Val
(FV Bonn) [15, 16, 17]. Nevertheless, FVL is responsible for about 95% of cases of APC
an
resistance. FVR2 (H1299R) also exhibits reduced APC cofactor activity and can cause
mild APC resistance, showing a lower thrombotic risk as compared to FVL [15, 18]. The
prothrombin mutation — G to A nucleotide change at 20210 in the 3'-untranslated region
M
of the prothrombin (F2) gene (PT G20210A) — leads to an impaired F2 3’-end cleavage
signal, resulting in RNA accumulation and thus, increased prothrombin synthesis [19]. This
ed
Other still undefined mechanisms could contribute to the risk of thrombosis in carriers of
PT G20210A including other genetic lesions which could be in linkage disequilibrium with
Ac
PT G20210A mutation. From the clinical point of view, FVL currently represents the most
common known hereditary defect predisposing to VTE: heterozygotes showed an
increased annual risk of VTE from 1 in 1,000 to 3-8 in 1,000, whereas homozygotes
exhibited an annual risk of 80 in 1,000 [22, 23]. As for PT G20210A, heterozygous carriers
present with an increased risk for VTE, with a relative risk (RR) of 2 to 3, overall slightly
lower than the risk associated with FVL [24, 25, 26]. In homozygous individuals the risk
has not clearly defined yet but in a recent study a RR of 5 (95% CI 2.1–11.92) was shown
compared to non-carriers [25]. Interestingly enough, carriers of both mutations (double
heterozygous for FVL and prothrombin mutation) have been reported to present with a six-
time higher VTE risk than their non-carrier relatives, even though a recent meta-analysis
found the risk of double heterozygosity to be similar to that observed in FVL alone [27, 28].
These discrepancies may be related mainly to the selection of the populations and to
different study design.
Antithrombin is one of the most important natural anticoagulants of the coagulation system
that inhibits several activated factors including thrombin, factor IXa, Xa, XIa and XIIa.
t
Heterozygous mutations in the AT gene can result in AT defects that are characterized by
ip
reduced inhibition of factor Xa and thrombin and, as a consequence, by increased
cr
thrombin generation and activity [2]. More than 250 genetic lesions have been identified in
patients with AT defects, including missense and nonsense point mutations, small or large
us
insertions and deletions [29]. The two more common types of defects are the so-called
“Type I”, a quantitative defect resulting in a decreased synthesis of a functional protein;
an
and Type II, a qualitative defect with normal levels of an abnormal protein with impaired
functional activity. Type II is further divided into three subtypes related to impair binding to
the enzyme reactive sites; subtype IIb is due to mutations in the heparin-binding sites;
M
subtype IIc is characterized by pleiotropic defects affecting both antigen concentration and
heparin binding site or binding to enzyme reactive sites [29, 30]. Cases of homozygous AT
ed
defects were rarely reported so far mainly involving the heparin-binding site, indicating that
homozygosity for type I or other type II subtypes is associated with embryonic lethality [31,
32]. The absolute risk of a first VTE in asymptomatic carriers of AT deficiency belonging to
pt
families with a symptomatic proband is approximately 2% per year [26, 30]. A large
population-based study showed that AT deficiency was associated with a five-fold (95% CI
ce
0.7– 34) increased risk of a first episode of deep venous thrombosis [33].
Protein C and protein S are vitamin K-dependent glycoproteins synthesized in the liver.
Ac
The activated form of protein C (APC) is an important natural anticoagulant that, along with
its co-factor PS, decreases thrombin generation by inhibiting factors Va and VIIIa [34].
Therefore, inherited deficiencies of each of the two determine increased thrombin
generation and predisposition to thrombosis. Protein C deficiency is inherited as an
autosomal dominant trait, and is classified into type I (quantitative) and type II (qualitative)
defects [4, 35]. Unlike AT deficiency, homozygous or double heterozygous PC deficiency
does not determine fetal death, but newborns with these severe thrombophilic conditions
may develop purpura fulminans characterized by severe thrombosis of small dermal
vessels, resulting in the ischaemic necrosis of extremities [36]. More than 200 mutations,
mostly missense, in the PC gene (PROC) have been described so far responsible for the
different types of defects [37].
t
reduced functional activity; or dysfunctional PS), and type III (normal or near normal
ip
plasma levels of total antigen and reduced free antigen and functional activity) [2, 4]. More
than 200 different mutations in the PROS1 gene responsible for PS defects have been
cr
identified, mostly being missense mutations or short deletions or insertions [4]. From the
us
clinical point of view, heterozygous PC deficiency is associated with a 4- to 6.5-fold
increased risk of VTE, while homozygous deficiency results in severe thrombotic
complications in the foetus, neonates or children, as mentioned previously [26]. The risk of
an
VTE associated with PS deficiency is still a matter of debate: family studies have
suggested a risk comparable to that observed in PC deficiency, but population studies
M
suggest a lower risk [26]. As in PC deficiency, homozygous PS deficiency may cause
severe purpura fulminans in neonates.
ed
Non-O blood group can be considered the most frequent genetic risk factor associated
with VTE. The prothrombotic effect is probably carried by increased levels of von
ce
Willebrand factor (VWF) and factor VIII, as mean levels of these factors are ~25% higher
in individuals with non-O blood groups than in those with O-blood group [39]. The
underlying mechanism for high VWF levels is the addition of A and B antigens to the
Ac
It can happen that heterozygous FVL carriers present with a concomitant heterozygous F5
t
gene mutation responsible for FV deficiency, resulting in the 50% of FV plasma levels
ip
being all FVL. This is the case of the so-called pseudo-homozygous FVL which show a
cr
severe APC resistance and a stronger tendency towards thrombosis as compared to
heterozygous FVL alone [9]. In pseudo-homozygotes, APC-resistance levels are
us
consistent with homozygosity though DNA testing shows heterozygous FVL. This
discrepancy between the genotype (heterozygous FVL) and the laboratory (severe APC
an
resistance) or clinical phenotypes (severe thrombotic tendency) should prompt further
analyses to exclude the presence of pseudo-homozygosity. Indeed, the thrombotic risk in
pseudo-homozygous patients is as high as that observed in homozygous individuals [43].
M
High plasma levels of procoagulants, such as factor VIII, IX, X, XI, and fibrinogen can
increase the risk of VTE and should therefore be included among the gain-of-function
ed
thrombophilia abnormalities [4]. However, the genetic basis behind elevated levels of
these procoagulants is only partially known. The extent of the increased risk of VTE
pt
ranges from 1.6-fold for plasma factor X levels >90th percentile, to fourfold for a fibrinogen
level >5.0 g/l [4]. More specifically, individuals with sustained elevations of factor VIII (i.e.
ce
serum concentrations ≥150 IU/dL) have a reported RR of VTE 5 times that observed in
those with levels <100 IU/dL [44]. The same FVIII elevation found among first-degree
relatives could indicate a hereditary transmission. A genetic polymorphism in the low-
Ac
Levels of FIX antigen >129 U/dl are associated with a 2.3-fold increased risk of VTE
(95%CI, 1.6-3.5) [47]. Factor IX Malmö is an A>G sequence variant (rs6048) in the F9
gene associated with VTE, although the prothrombotic mechanism remains unknown [48].
Factor IX Padua is a gain-of-function mutation in the F9 gene (R338L) discovered by our
group, which was detected in some components of a single family symptomatic for VTE
and carrying extremely high plasma factor IX activity (eight times the normal levels)
contrasting with normal antigen levels [10]. The mutation has not been reported in other
cohorts of patients with VTE so far [49].
Elevations of factor XI >90th percentile were found to be an independent risk factor for VTE
with a 2-fold increased risk [50]. No genetic mutations responsible for increased FXI levels
t
have been identified so far.
ip
A novel gain-of-function mechanism defined as “resistance to antithrombin” has been
cr
identified in families with thrombophilia. The molecular basis is a missense mutation at the
prothrombin Arg596 residue (exon 14) leading to a defect of thrombin–antithrombin
us
binding and impaired inhibition by AT of the mutated thrombin [51]. The first prothrombin
mutation causing antithrombin-resistance was reported in 2012 (Prothrombin Yukuhashi)
an
[51]. Subsequently, similar cases were recorded in Serbia, India and Italy [52, 53, 54]. The
five families carry three different mutations on the same Arginine 596, and namely:
Prothrombin Yukuhashi Arg596Leu [51], Prothrombin Belgrade and Amrita Arg596Gln [52,
M
54] and Prothrombin Padua 2, Arg596Trp [53]. Point mutations of prothrombin Arg596
have been identified in several thrombotic patients of different race and ethnicity
ed
worldwide. However, the real incidence of these mutations and the associated thrombotic
risk have not been clearly defined yet. It is worth mentioning that these novel hereditary
mechanisms of thrombophilia are rare and currently do not affect much the clinical
pt
practice. However, clinicians should think even to these novel mutations or to other new
potential genetic mechanisms when approaching patients or families with unexplained
ce
3. Acquired thrombophilia
Ac
The term thrombophilia also includes the hypercoagulable states caused by acquired
disorders of haemostasis. Acquired disorders can foster a prothrombotic state via elevated
procoagulant factors, reduced anticoagulants, pro-inflammtory/autoimmune mechanisms,
as well as multiple alterations in homeostatic regulation of blood coagulation. The main
acquired disorders associated to thrombophilia are antiphospholipid antibody syndrome,
hyperomocisteinaemia, transiently/permanently increased levels of procoagulant factors,
and finally, decreased levels of natural anticoagulants.
3.1 Antiphospholipid antibody syndrome
t
antibodies [aPL], mainly anticardiolipin and antiphosphatidylserine antibodies) or their
ip
associated plasma proteins, mainly beta-2 glycoprotein I (β2GPI), or the presence of a
lupus anticoagulant (LAC). A diagnosis of APS is made if at least one of the above
cr
mentioned clinical manifestations occurs and at least one of the laboratory antibodies is
us
identified in two or more occasions [56]. The main prothrombotic mechanism in APS
involves the binding of aPL to β2GPI on cellular surfaces leading to the following
consequences: i) up-regulation of the expression of potentially prothrombotic adhesion
an
molecules on the cell-surface (e.g. E-selectin, tissue factor); ii) down-regulation of tissue
factor pathway inhibitor activity; iii) impairment of APC activity; iv); hypofibrinolysis (via
M
reduction of tissue plasminogen activator-tPA activity); v) complement activation [55, 57].
The risk of a first VTE among asymptomatic subjects who are positive for LAC,
anticardiolipin, and anti–β2GPI antibodies — so-called triple positive patients — is 5.3%
ed
per year. Importantly, 44% of triple positive APS patients will undergo recurrent thrombosis
over a 10-year follow-up period (notwithstanding anticoagulant therapy) [58].
pt
3.2 Hyperhomocysteinaemia
ce
The amino acid homocysteine is formed from the demethylation of methionine and its
plasma levels depend on two main mechanisms: remethylation to methionine (by
methionine synthase which requires both vitamin B12 and N5-methyltetrahydrofolate
Ac
t
ip
is not associated with an increased risk of thrombosis [61].
cr
The levels of pro- and anticoagulant factors are genetically controlled though they can be
us
influenced by age and acquired conditions, and mostly inflammation [3]. Indeed, the
majority of the acquired risk factors for thrombosis — surgery, trauma, acute medical
an
conditions, inflammation, malignancy and myeloproliferative disorders, obesity — are
characterized by elevated levels of procoagulant factors, particularly factor VIII. Moreover,
acquired risk factors for thrombosis, and namely pregnancy, hormonal therapy, cancer,
M
nephrotic syndrome are also associated with reduced anticoagulant factors levels. Table 2
summarizes the risks of VTE in acquired thrombophilic conditions while showcasing the
ed
trend of pro- and anticoagulant factors levels. Particularly, the hypercoagulability observed
in pregnancy is due to increased levels of VWF, fibrinogen, factors VII, VIII, X; decreased
PS and acquired APC resistance [62]. The mechanism underlying hypercoagulability in
pt
cancer is quite complex [63, 64]. Briefly, tissue factor is highly expressed in tumor cells;
activated platelets release procoagulant microvesicles (MV) providing a procoagulant
ce
surface; natural anticoagulants levels are also frequently reduced. VTE is a frequent
leading cause of death in cancer, and occurs in about 20% of all cases [62].
Ac
Myeloproliferative neoplasms have a high incidence of both venous (10%) and arterial
thrombotic complications (3%). The main causes of hypercoagulability are the following:
endothelial dysfunction, leukocytosis, vascular cell activation, high platelet-induced
thrombin generation, decreased levels of PS (possibly due to absorption on the expanded
blood cell surfaces) and acquired APC resistance, as well as elevated plasma viscosity
[65].
t
ip
(0.14–0.67 per 100 person-years for FVL; 0.05–0.42 per 100 person-years for prothrombin
mutation) [3, 4]. Interestingly, low borderline levels of AT, PC, and PS also have been
cr
associated with a twofold increased risk of VTE, comparable with that of mild
thrombophilia [66].
us
VTE can be considered like a double- or triple-hit process, which means a single risk factor
an
(e.g., heterozygous FVL) will provide an element of risk that is unlikely to singlehandedly
cause thrombosis, but an additional risk factor (e.g., surgery) may provide the trigger for
overt thrombosis to occur [67]. Indeed, carriers may remain asymptomatic for many years,
M
suggesting that the development of VTE may require further triggering factors. In family
studies conducted on carriers of natural anticoagulants deficiencies, about half of
ed
thrombotic events were triggered by a concomitant acquired risk factor [4]. Thus,
interactions between genetic and acquired risk factors should be considered to determine
the overall prothrombotic profile of patients.
pt
Indeed, the incidence of VTE in patients with AT, PC, or PS defects with exposure to
ce
acquired risk factors is estimated to be 1.2–8.1 per 100 person-years, whereas said
incidence in mild thrombophilia is much lower during exposure to acquired risk factors,
around 0.2-2.3 per 100 person-years [2]. First of all, a positive familial history of VTE is
Ac
“per se” a strong risk factor for VTE and should be always taken into consideration when
evaluating a patient’s thrombotic risk. The second element is age; in fact, in family cohort
studies, carriers of AT, PC, or PS defects, exhibited VTE at a younger age (median 29
years) than those with FVL or PT G20210A (median 40 years) [44, 68]. Recent findings
from our group showed that circulating MVs may also concur to the occurrence of VTE in
hereditary thrombophilic carriers — both in mild and severe states — as well as in APS
[69, 70, 71]. Circulating MVs, which may constitute an epiphenomenon of the
thrombophilic state itself, could be up-regulated in acute conditions thus enhancing the
overall hypercoagulable state up to the threshold of VTE occurrence [69, 70, 71].
Surgery, immobilization, and pregnancy are some of the additional risk factors for
thrombosis that may prompt to consider thromboprophylaxis in patients with hereditary
thrombophilia. Here, we summarize the latest evidence on prevention of VTE in
thrombophilia patients in the most common high-risk situations.
t
ip
Because of the risk of bleeding complications that can occur during thromboprophylaxis,
the risk-benefit ratio of antithrombotic therapy as primary prevention for surgery-related
cr
VTE in at-risk patients need to be carefully assessed. In 2012, the American College of
Chest Physicians (ACCP) Guidelines suggest the use of thromboprophylaxis with low-
us
molecular-weight heparin (LMWH) after general and abdominal-pelvic surgery in patients
at moderate risk for VTE (~3.0%; Caprini score 3-4) who did not present with a high risk for
an
major bleeding [72]. The Caprini Scoring system is a tool to identify patients at increased
postoperative risk for VTE [73]. Interestingly enough, 3 points were assigned to the
presence of FVL or PT G20201A, LAC, elevated anticardiolipin antibodies, elevated serum
M
[74]. Interestingly, a positive family history of VTE represents itself an additional risk factor
(3 points in Caprini score), irrespective of a confirmed thrombophilic state. Thus, the
detection of inherited thrombophilia is not likely to make a significant contribution to the
pt
stratification of the risk if family history of VTE is already present. Likewise, there is still no
ce
t
ip
general and abdominal-pelvic surgery in individuals at high risk for VTE (~6.0%; Caprini
score ≥5). [72].
cr
us
6. Prevention of pregnancy-related VTE
an
Decisions whether using of prophylactic anticoagulation during pregnancy to prevent VTE
depend on the benefit-risk ratio. The rate of clinically relevant maternal bleeding due to the
LMWH use is about 2%, mainly associated with the delivery (1%) or wound haematoma
M
(0.6%) [79]. On the other hand, in a systematic review of 9 case-control studies (n=2526
patients) considering the association between thrombophilia and pregnancy-associated
ed
VTE, the highest risk was associated to homozygous FVL or PTG20201A [80].
Deficiencies of AT, PC, and PS were associated with moderate risk increases, while
pregnant women with mild thrombophilias presented with a lower risk of VTE. Considering
pt
a basal incidence of VTE complications during pregnancy of about 1/1000 deliveries, the
calculated absolute risks suggest a low prothrombotic profile (0.5–1.2% of affected
ce
t
in those cases [4, 81, 83, 84, 85]. Conversely, antenatal clinical surveillance is believed to
ip
be sufficient for pregnant women with mild thrombophilia, and clinicians should consider
antenatal LMWH prophylaxis only in the presence of additional risk factors (positive family
cr
history, hypo mobility, obesity, age >35 years, gross varicose veins) [4]. As for post-
us
partum, antithrombotic LMWH prophylaxis is recommended for 4-6 weeks in carriers of
severe thrombophilia. The same is true of mild thrombophilia, even though data are
inconsistent, with antithrombotic prophylaxis ranging from at least 7 days to up to 6 weeks
an
post-partum but only for women carrying additional risk factors [4]. ACCP guidelines are
more restrictive in thromboporophylaxis indications pointing out the positive family history
M
more than the carriership of thrombophilia [86]. When the decision is made to use
antepartum prophylaxis, it should be initiated early in the pregnancy. Finally, prophylaxis is
recommended after caesarean delivery in case of a known thrombophilia. As for AT
ed
or has a history of VTE. Indeed, it was reported that in AT-deficient patients with recent or
recurrent thrombosis, the administration of AT during labor successfully prevented
ce
Combined oral contraceptives (COC) therapy can increase the risk of VTE by two to
ninefold. This is due both to the dose of oestrogen and the type of progestogen contained
in the preparations. The so called “third-generation pills” containing desogestrel or
gestodene are associated with a twofold increased risk of VTE compared to levonorgestrel
(present in the “second-generation” pills) [87]. Additionally, the most recent “fourth-
generation” type of COC containing progestins such as drospirenone, nomegestrol acetate
or dienogest present with 3-fold increased risk of VTE compared to the second-generation
pills [88]. A multiplicative effect of COC use and inherited thrombophilia on the risk of VTE
was observed, with a two to fivefold increase in women with both risk factors versus either
risk factor considered individually [89]. Interestingly, a recent study on pre-menopausal
women showed a statistically significant interaction between COC use and presence of
FVL on VTE risk (OR 1.37, 95%CI 1.06–1.77). This interaction appeared higher for
drospirenone (OR 1.99 [95%CI 1.18–3.38]) or third-generation cyproterone acetate users
(OR 1.71 [95%CI 1.20–2.45]), but not significant for 1st or 2nd COC users [90]. Recently,
WHO Medical Eligibility Criteria confirmed that COC use in women with hereditary
t
ip
thrombophilias is associated with an unacceptable health (life threatening) risk [91]. A
recent meta-analysis regarding 12 case–control and three cohort studies showed that mild
cr
thrombophilia increased the risk of VTE in COC users by 6-fold (RR 5.89; 95%CI 4.21–
8.23) (14 studies considered), while the presence of severe thrombophilia enhanced the
us
risk in COC users by approximately 7-fold (RR 7.15; 95%CI 2.93–17.45) (3 studies
considered) [89]. VTE incidence in COC users with mild thrombophilia was 0.49 (95%CI
an
0.18–1.07) to 2.0 (0.3–7.2) per 100 pill-years; it was 0.86 (95%CI, 0.10–3.11) per 100 pill-
years in COC users double heterozygous or homozygous for FVL or PT G20201A and 4.3
(95%CI 1.4–9.7) to 4.62 (95%CI 2.5–7.9) per 100 pill-years in COC users who were
M
carriers of AT, PC or PS defects. These results confirm that COC should not be
administered to women with severe hereditary thrombophilia, including asymptomatic
ed
women. Possible options with similar contraceptive efficacy include progestogen-only pills,
intrauterine devices (IUDs) containing only levonorgestrel and Cu-IUDs containing at least
300 mm2 Cu [89]. Thrombophilia screening is not generally recommended before the use
pt
t
ip
can knowingly decide whether or not to be tested.
cr
A few studies evaluating the role of FVL and PT G20210A on the risk of cancer-associated
us
thrombosis have been published [93]. Overall, despite conflicting results, it would appear
that cancer patients carrying either of these mutations tend to show an increase risk of
an
thrombosis. In a case–control study by Blom et al. [94] on 205 adult cancer patients, the
risk of VTE was 2-fold higher in patients with than those without FVL (adjusted OR: 2.2
[95%CI 0.3-17.8]). Moreover, patients with cancer and PT G20210A had an OR for VTE of
M
4.1 (95%CI 0.3-60.8) compared with those without mutation. In a study by a Turkish group,
the prevalence of FVL was significantly higher (30.2%) in cancer patients with VTE
ed
compared to those without VTE (3.7%, p <0.001) [95], while no significant difference in the
prevalence of PT G20210A was observed. Particularly, patients with cancer and central
venous catheters (CVC) who had inherited thrombophilia showed increased risk of VTE. In
pt
a meta-analysis by Dentali et al. [96] including 10 studies (211 cases and 860 controls)
increased risk of CVC-related thrombosis in carriers of FVL [OR 4.6 (95%CI 2.6-8.1)] and
ce
PT G20210A [OR 4.9 (95%CI 1.7-14.3)], respectively was shown. The measured
attributable risk of CVC-related thrombosis was 13.1% and 4.5% for FVL and PT
Ac
t
ip
approximately 8-fold (RR 8.5, 95%CI 4.4–17.4). Even though data are still limited, it
appears that thrombophilia could increase the risk of cancer-associated thrombosis.
cr
However, inherited thrombophilia testing is not currently recommended in the strategies of
prophylaxis and treatment of VTE in cancer patients.
us
9. Prevention of economy class syndrome
an
The ‘economy class syndrome’ is defined as the occurrence of thrombotic complications
during long-haul flights that manifest mainly in passengers travelling in economy class. In
M
normal healthy individuals the estimated absolute risk of VTE on flights lasting more than 4
h was about 1 in 6000 [100]. In a meta-analysis [101] of 14 studies including 4055 cases of
ed
VTE occurred during both air and overland trips lasting up to 8 h and with a follow-up time
post-journey ranging from two to eight weeks, the overall RR of VTE was 2.8 [95%CI 2.2–
pt
3.7] with an approximate 18% increase in the risk at each increment of 2 h in travel time.
This risk increased up to 26% if only air travels were considered. In travellers with
ce
thrombophilia, the risk of VTE was 16.8 times higher (95%CI 3.8–74.7) than in non-
thrombophilic, non-travelers, accounting for a synergistic interaction [102]. In the case of
thrombophilia, antithrombotic measures are of paramount importance. Travellers should
Ac
be informed of the potential thrombotic risks, encouraged to exercise regularly with short
walks along the aisles, and avoid dehydration [100]. The Aerospace Medical Association
(AsMA) published guidelines on optimal antithrombotic prophylaxis in subjects who travel
by air and patients with known thrombophilia is considered at high risk for thrombosis
[103]. Recommendations for travellers with high thrombotic risk on flights lasting over 8 h
are: avoidance of constrictive clothing around the lower extremities or waist; adequate
hydration; repeated calf muscle contraction. A perceived higher risk of VTE may prompt
active thromboprophylaxis measures such as properly fitted below-knee compressive
stockings (15-30 mmHg of pressure at the ankle) or a single prophylactic dose of LWMH,
injected prior to departure.
Post-thrombotic syndrome (PTS), the most common chronic complication of deep vein
thrombosis (DVT), causes chronic limb pain, swelling and leg ulcers, which reduces the
quality of life of affected patients [104]. Previous studies reported that 20–50% of patients
with DVTs developed PTS [104]. A study by our group considering 191 patients with
t
thrombophilia and 339 without, showed that the adjusted HR for the development of PTS
ip
in thrombophilic versus non-thrombophilic patients was 1.23 (95%CI, 0.92–1.64) [42].
cr
Specifically, the adjusted HR for the development of PTS in carriers was 0.42 (95%CI,
0.20–0.88; P = 0.02) for FVL, 0.81 (0.36–1.37) for LAC, 0.96 (0.29–3.82) for PC
us
deficiency, 1.08 (0.29–2.70) for PS deficiency, and 1.33 (0.68–2.58) for PT G20210A. Of
the two patients with AT deficiency, neither developed PTS. A meta-analysis by
an
Rabinovich et al. [105] considered 16 studies (13 assessing FVL, 10 PT G20210A, 5 PC
and PS deficiencies, 3 AT deficiency, 4 elevated FVIII, and 6 aPL). The Authors confirmed
that none of the studies acknowledged any of the thrombophilias as predictive of PTS.
M
Unexpectedly, FVL and PT G20210A even appeared to protect against PTS in studies
including patients with first and recurrent DVT events, and studies in which over 50% of
ed
patients had an unprovoked event. A very recent Japanese Registry gathered data on
1218 patients with DVT who completed 3 years of follow-up [104]. The Authors showed
that chronic kidney disease (OR 2.21, 95% CI 1.45–3.39), leg swelling (OR 4.15, 95%CI
pt
2.25–7.66), no transient risk factors for VTE (OR 2.39, 95%CI 1.55–3.67), active cancer
(OR 3.66, 95%CI 2.30–5.84), and thrombophilia (OR 2.07, 95%CI 1.06–4.04) were
ce
independent risk factors for the development of PTS. Patients with thrombophilia were 79
(6.1%) and, interestingly, they considered only severe thrombophilia (APS; PC, PS and AT
Ac
deficiencies). This is the only study where severe thrombophilia appears to be associated
with the development of PTS. At the moment, the association between thrombophilia and
PTS is not deemed important enough to warrant a thrombophilia screening or different
secondary prophylaxis strategies in thrombophilic carriers. Needless to say, this
conclusion is based on low levels of evidence due to the lack of properly designed studies.
Finally, a recent study by our group suggested that non-O blood type might be a risk factor
for the development of PTS, as individuals with non-O blood group were associated with a
significantly higher PTS occurrence (HR 1.53, 95% CI, 1.05–2.24; p = 0.028) than O group
[106]. Although larger studies are needed to confirm our results, blood group might be an
additional element to take into account in the evaluation of the strategies to prevent PTS.
Fifty-three years following the first description of a hereditary prothrombotic condition (AT
deficiency) we have greatly increased our knowledge on both hereditary and acquired
causes of hypercoagulability which can temporary or long-life predispose carriers to VTE.
t
Focusing on hereditary thrombophilia, currently available data uncovered a thrombotic risk
ip
gradient from carriers of natural anticoagulant deficiencies and in the presence of
cr
homozygous defects or multiple abnormalities (severe thrombophilia) to heterozygotes for
FVL and prothrombin G20210A (mild thrombophilia). Additionally, novel prothrombotic
us
hereditary conditions have been recently described and the thrombotic risk conferred by
them is still unknown. Among the most common acquired prothromboitc conditions,
an
clinicians have to consider APS and hyperhomocisteinaemia, as well as all the conditions
characterized by a temporary acquired increase in procoagulant and/or decrease in
anticoagulant factors. Importantly, the management of a patient with a thrombophilic
M
condition should take into consideration other (genetic and/or acquired) coexisting risk
factors for first or recurrent VTE in order to determine the necessity and duration of
ed
prevention (primary prophylaxis). The main role of the clinicians is to individualize case-by-
case the approach for the prevention of VTE and consider each patient’s risk taking into
account strong situational risk factors (e.g., surgery, pregnancy, therapies, etc.). Notably,
pt
In addition, the knowledge of the carriership status of the so-called severe thrombophilia
can be important to properly counsel asymptomatic relatives — particularly women of
Ac
Novel severe thrombophilic conditions have been identified in the last few years, and
namely, factor IX Padua [10], prothrombin Yukuhashi [52], prothrombin Belgrade [52],
prothrombin Amrita [54], and prothrombin Padua 2 [53]. Even more new genetic defects
predisposing to thrombosis are likely to be discovered soon. The discovery of novel
genetic mutations undoubtedly opens new doors to understanding the mechanisms of
thrombosis. Studies on thrombophilia need to be conducted anew, taking into account a
more thorough evaluation and definition of thrombophilia. Granted, we now possess a
wealth of knowledge as it pertains to the slight impact of mild thrombophilias on the overall
thrombotic risk; nevertheless, there are still areas of doubt and uncertainty regarding
severe and novel thrombophilia. Future research projects should focus on identifying novel
thrombophilic factors in order to explain (and possibly prevent) more cases of unprovoked
t
ip
thrombosis, and to clarify the molecular mechanisms underlying the complex interaction
between genetic and environmental risk factors for thrombosis. Finally, the more favorable
cr
safety and efficacy profiles of direct oral anticoagulants recently introduced in clinical
practice should be considered in the light of future strategies for prevention and treatment
us
of VTE in patients with inherited or acquired thrombophilia.
Article Highlights
an
• Thrombophilia is a clinical condition defined as either an inherited or acquired
abnormality of haemostasis predisposing to venous thromboembolism (VTE).
M
• Individual’s ABO blood group is the most common genetic risk factor for VTE to
remember.
Funding
t
The authors have no relevant affiliations or financial involvement with any organization or
ip
entity with a financial interest in or financial conflict with the subject matter or materials
cr
discussed in the manuscript. This includes employment, consultancies, honoraria, stock
ownership or options, expert testimony, grants or patents received or pending, or royalties.
us
Reviewer disclosures
References
M
Papers of special note have been highlighted as either of interest (•) or of considerable
interest (••) to readers.
ed
1. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol.
2008;143(2):180-90.
2. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical
pt
2014;7(6):757-65.
• The review clearly summarizes epidemiology and management of hereditary
thrombophilia
Ac
t
prothrombin corresponding to Arg596 cause antithrombin resistance and
ip
thrombomodulin resistance. Thromb Haemost. 2016;116(6):1022-1031.
12. Wu O, Bayoumi N, Vickers MA, et al. ABO(H) blood groups and vascular disease: a
systematic review and meta-analysis. J Thromb Haemost. 2008;6(1):62-9.
cr
13. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously
unrecognized mechanism characterized by poor anticoagulant response to
activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad
us
Sci U S A. 1993;90(3):1004-8.
14. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous
thrombosis. N Engl J Med. 1994;330(8):517-22.
an
15. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV
Hong Kong and FV Cambridge. Blood. 2002;100(2):524-30.
16. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J
Thromb Haemost. 2010;8(3):445-53.
M
17. Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in
Hong Kong Chinese. Blood. 1998;91(4):1135-9.
18. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from
ed
t
of Hereditary Antithrombin Deficiency. Ann Pharmacother. 2016;50(9):758-67.
ip
• The review fully discuss epidemiology, diagnosis, management and challenging
situation of antithrombin hereditary deficiency.
31. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the
cr
subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb
Haemost. 1987;58(4):1094.
32. Rossi E, Chiusolo P, Za T, et al. Report of a novel kindred with antithrombin
us
heparin-binding site variant (47 Arg to His): demand for an automated progressive
antithrombin assay to detect molecular variants with low thrombotic risk. Thromb
Haemost. 2007;98(3):695-7.
an
33. Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb
Thrombolysis. 2011;31(3):275-81.
34. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta. 2000;1477(1-
2):349-60.
M
35. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis,
clinical syndromes, and management. Blood. 1996;87(9):3531-44.
36. Price VE, Ledingham DL, Krumpel A, et al. Diagnosis and management of neonatal
ed
Haemost. 1995;73(5):876-89.
38. Dahlback B. Inhibition of protein Ca cofactor function of human and bovine protein
S by C4b-binding protein. J Biol Chem. 1986;261(26):12022-7.
ce
39. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the
diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-5.
40. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo
survival of human factor VIII/von Willebrand factor protein. J Biol Chem.
Ac
1977;252(15):5538-46.
41. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic
risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb
Hemost. 2012;38(5):535-48.
42. Spiezia L, Campello E, Bon M, et al. ABO blood groups and the risk of venous
thrombosis in patients with inherited thrombophilia. Blood Transfus. 2013;11(2):250-
3.
43. Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites
resulting in enhanced thrombotic tendency. Blood. 2005;106(7):2363-5.
44. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in
patients with first venous thrombosis: results from a retrospective family cohort
study on absolute thrombotic risk for currently known thrombophilic defects in 2479
relatives. Blood. 2009;113(21):5314-22.
45. Vormittag R, Bencur P, Ay C, et al. Low-density lipoprotein receptor-related protein
1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk
of venous thromboembolism. J Thromb Haemost. 2007;5(3):497-502.
46. Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the
coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII
activity levels. Blood. 2007;109(9):3713-24.
47. van Hylckama Vlieg A, van der Linden IK, Bertina RM, et al. High levels of factor IX
increase the risk of venous thrombosis. Blood. 2000;95(12):3678-82.
48. Bezemer ID, Arellano AR, Tong CH, et al. F9 Malmo, factor IX and deep vein
t
thrombosis. Haematologica. 2009;94(5):693-9.
ip
49. Koenderman JS, Bertina RM, Reitsma PH, et al. Factor IX-R338L (Factor IX Padua)
screening in a Dutch population of sibpairs with early onset venous
thromboembolism. Thromb Res. 2011;128(6):603.
cr
50. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI
as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696-701.
51. Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation
us
conveying antithrombin resistance. N Engl J Med. 2012;366(25):2390-6.
52. Djordjevic V, Kovac M, Miljic P, et al. A novel prothrombin mutation in two families
with prominent thrombophilia--the first cases of antithrombin resistance in a
an
Caucasian population. J Thromb Haemost. 2013;11(10):1936-9.
53. Bulato C, Radu CM, Campello E, et al. New Prothrombin Mutation (Arg596Trp,
Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler
Thromb Vasc Biol. 2016;36(5):1022-9.
M
54. Sivasundar S, Oommen AT, Prakash O, et al. Molecular defect of 'Prothrombin
Amrita': substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding
loop of prothrombin. Blood Cells Mol Dis. 2013;50(3):182-3.
ed
58. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed
with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-42.
59. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview.
Arch Pathol Lab Med. 2007;131(6):872-84.
Ac
t
68. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, et al. The pathogenesis of venous
ip
thromboembolism: evidence for multiple interrelated causes. Ann Intern Med.
2006;145(11):807-15.
69. Campello E, Radu CM, Spiezia L, et al. Modulating thrombotic diathesis in
cr
hereditary thrombophilia and antiphospholipid antibody syndrome: a role for
circulating microparticles? Clin Chem Lab Med. 2017;55(7):934-943.
70. Campello E, Spiezia L, Radu CM, et al. Circulating microparticles in carriers of
us
factor V Leiden with and without a history of venous thrombosis. Thromb Haemost.
2012;108(4):633-9.
71. Campello E, Spiezia L, Radu CM, et al. Circulating microparticles and the risk of
an
thrombosis in inherited deficiencies of antithrombin, protein C and protein S.
Thromb Haemost. 2016;115(1):81-8.
72. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical
patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
M
College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012;141(2 Suppl):e227S-e277S.
73. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon.
ed
2005;51(2-3):70-8.
74. Coppola A, Tufano A, Cerbone AM, et al. Inherited thrombophilia: implications for
prevention and treatment of venous thromboembolism. Semin Thromb Hemost.
2009;35(7):683-94.
pt
t
services/guidelines/gtg37a. 2015.
ip
86. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic
therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th
ed: American College of Chest Physicians Evidence-Based Clinical Practice
cr
Guidelines. Chest. 2012;141(2 Suppl):e691S-e736S.
87. Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk
of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
us
88. Larivée N, Suissa S, Coulombe J, et al. Drospirenone-Containing Oral
Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of
Risk in First-Time Users and Restarters. Drug Saf. 2017;40(7):583-596.
an
89. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, et al. Combined oral
contraceptives, thrombophilia and the risk of venous thromboembolism: a
systematic review and meta-analysis. J Thromb Haemost. 2016;14(7):1393-403.
•• This systematic review and meta-analysis summarizes the additional risk of
M
venous thromboembolism in combined oral contraceptives-users and
thrombophilia
90. Hugon-Rodin J, Horellou MH, Conard J, et al. Type of combined contraceptives,
ed
2008;36(3-4):131-6.
94. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and
the risk of venous thrombosis. JAMA. 2005;293(6):715-22.
95. Eroglu A, Ulu A, Cam R, et al. Prevalence of Factor V 1691 G-A (Leiden) and
Ac
t
Services. Aerosp Med Hum Perform. 2015;86(7):657-8.
ip
104. Nishimoto Y, Yamashita Y, Morimoto T, et al. Risk factors for post-thrombotic
syndrome in patients with deep vein thrombosis: from the COMMAND VTE registry.
Heart Vessels. 2018.
cr
105. Rabinovich A, Cohen JM, Prandoni P, et al. Association between thrombophilia and
the post-thrombotic syndrome: a systematic review and meta-analysis. J Thromb
Haemost. 2014;12(1):14-23.
us
106. Spiezia L, Campello E, Valle FD, et al. ABO blood group and the risk of post-
thrombotic syndrome. Ann Hematol. 2018;97(6):1057-1060.
an
M
ed
pt
ce
Ac
Ac
ce
pt
ed
M
an
us
cr
ip
t
Table 1. Increased thrombotic risk in hereditary and acquired thrombophilia
Hereditary thrombophilia
Factor V Leiden
Heterozygous 3-7x
Homozygous 80x
t
Prothrombin G20210A
ip
Heterozygous 2-3x
cr
Homozygous 5x
us
AT deficiency 5x
AT resistance 2-3x
Acquired thrombophilia
ce
Adapted from [2-4, 62], Phillippe HM et al. Inherited Thrombophilia. J Pharm Pract. 2014; 27(3) 227-233;
Makris M. Thrombophilia: grading the risk. Blood. 2009;113(21):5038-9; Bauer KA et al. Overview of the
causes of venous thrombosis. www.uptodate.com ©2018 UpToDate.
cr
Acquired thrombophilia Relative risk Haemostatic changes
for a first VTE
us
Surgery 1.7-2.8x • release or exposure of TF
• ↓ AT
Trauma 3-5x • hypofibrinolysis (↑ PAI-1)
an
• ↑ procoagulant factors (fibrinogen, VII, VIII,
X, vW)
Pregnancy 5-50x • ↓ protein S
M
• acquired APC resistance
• ↓ protein S
ed
• ↓ TFPI
• release of TF
Oestrogen–progestogen therapies 2-9x
• ↑ procoagulant factors
pt
• ↓ anticoagulant factors
Cancer 4-7x • platelet activation
ce
• ↑ procoagulant factors
• ↓ protein S
• acquired APC resistance
• ↑ platelet-induced thrombin generation
Ac
Adapted from [62-65,98], Sandor T. Travel thrombosis: pathomechanisms and clinical aspects.
Pathophysiology. 2008;15(4):243–52; Bauer KA et al. Overview of the causes of venous thrombosis.
www.uptodate.com ©2018 UpToDate.
TF: tissue factor; AT: antithrombin; PAI-1: plasminogen activator inhibitor-1; BMI: body mass index; vW: von
Willebrand; APC: activated protein C; TFPI: tissue factor pathway inhibitor, tPA: tissue plasminogen
activator.
t
ip
cr
us
an
M
ed
pt
ce
Ac